A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients With Huntington's Disease
Phase of Trial: Phase II
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Pridopidine (Primary)
- Indications Huntington's disease
- Focus Adverse reactions
- Acronyms Open PRIDE-HD
- Sponsors Teva Branded Pharmaceutical Products R&D
- 22 Aug 2017 Planned number of patients changed from 300 to 650.
- 22 Aug 2017 Planned End Date changed from 30 Sep 2017 to 20 Oct 2022.
- 22 Aug 2017 Planned primary completion date changed from 30 Sep 2017 to 20 Oct 2022.